Theranexus Optimizes Batten-1 Trial and Secures Funding

Theranexus SA (FR:ALTHX) has released an update.

Theranexus SA, a biopharmaceutical company, reported a cash position of €1.8 million as of 30 June 2024 and detailed progress on its Batten-1 program, including optimization for its pivotal Phase III trial. The company also announced the launch of a new equity line of €2.5 million over 24 months to finance this upcoming trial. These efforts are integral to the development of their drug candidate for juvenile (CLN3) Batten disease.

For further insights into FR:ALTHX stock, check out TipRanks’ Stock Analysis page.